Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2305-2312

  Sun, Shawn X ^a   Liu, Gordon G ^b   Christensen, Dale B ^c   Fu, Alex Z ^d  

^a Walgreens Health Services   (United States)

^b Peking University   (China)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antipsychotics; Economic; Hospitalization cost; Nonadherence; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

HEALTH CARE COST; HEALTH SURVEY; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; MENTAL HEALTH CARE; RECURRENCE RISK; REVIEW; SCHIZOPHRENIA; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; COST OF ILLNESS; HOSPITALIZATION; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; UNITED STATES;

EID: 35649004948     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X226050     Document Type: Review

References (47)

1. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
2. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
3. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia: 1991. Soc Psychiatr Epidemiol 1995;30:196-205
4. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999;60(Suppl 1):4-6
5. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105-22
6. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
7. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51
8. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-88
9. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005;22:319-62
10. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
11. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
12. Magura S, Laudet AB, Mahmood D, et al. Adherence to medication regimens and participation in dual-focus self-help groups. Psychiatr Serv 2002;53:310-16
13. Berger BA, Krueger KP, Felkey BG. The pharmacist's role in treatment adherence. Part 1: Extent of the problem. US Pharmacist 2004;29:50-4
14. Schoen MD, DiDomenico RJ, Connor SE, et al. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy 2001;21:1455-63
15. Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc 1998;38:574-85
16. Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995;152:1749-56
17. McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenia patients. J Nerv Ment Dis 1984;172:412-16
18. Caton CLM, Koh SP, Fleiss JL, et al. Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 1985;173:139-48
19. Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 1988;39:963-6
20. Casper ES, Regan JR. Reasons for admission among six profile subgroups of recidivists of inpatient services. Can J Psychiatry 1993;38:657-61
21. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;2:856-61
22. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the post-institutional era in the US. Pharmacoeconomics 1995;8:199-222
23. Delaney C. Reducing recidivism: medication vs psychological rehabilitation. J Psychosocial Nursing 1998;36:28-34
24. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
25. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
26. Al-Zakwani IS, Barron JJ, Bullano MF, et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003;19:619-26
27. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-16
28. Rittmannsberger H, Pachinger T, Keppelmüller P, et al. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 2004;55:174-9
29. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27:263-72
30. Kelly GR, Scott JE, Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990;28:1181-97
31. Corriss DJ, Smith TE, Hull JW, et al. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res 1999;89:269-74
32. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
33. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medical regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990;2:19-33
34. Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989;27:1159-66
35. Skaer TL, Sclar DA, Robinson LM. Noncompliance with antihypertensive therapy. Economic consequences. Pharmacoeconomics 1996;9:1-4
36. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10(Pt 2):144-51
37. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106-24
38. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-16
39. National and regional estimates on hospital use for all patients from the HCUP Nationwide Inpatient Sample (NIS). Available at http://hcupnet.ahrq.gov/ HCUPnet.jsp?Id=4BF191B03CAE83A4&Form=SelLAY&JS=Y&Action= %3E%3ENext%3E%3E&_LAY=Researcher [Last accessed June 23, 2007]
40. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11
41. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients. J Clin Psychiatry 1996;57:337-45
42. Harman JS, Manning WG, Lurie N, et al. Association between interruptions in Medicaid coverage and use of inpatient psychiatric services. Psychiatr Serv 2003;54:999-1005
43. Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003;31:188-96
44. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
45. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
46. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22
47. Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2007 Jun 25 [Epub ahead of print]